Efficiency and safety of Prostatex in patients with chronic prostatitis/chronic pelvic pain syndrome. Results of the phase IV prestige trial
- Authors: Morozov A.O.1, Vovdenko S.V.1, Maltsagova P.S.1, Spivak L.G.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
- Issue: No 2 (2023)
- Pages: 41-47
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/521571
- DOI: https://doi.org/10.18565/urology.2023.2.41-47
- ID: 521571
Cite item
Open Access
Access granted
Abstract
Introduction: A large number of both preclinical and clinical studies demonstrates the efficiency of bioregulatory peptides for the treatment of prostatitis and chronic pelvic pain syndrome (CPPS). A relatively new drug in this group is Prostatex, the active ingredient of which is bovine prostate extract.
Aim. To evaluate the effect of taking Prostatex on the intensity of CPPS, the sexual function, and the results of microscopy of expressed prostate secretions and urinalysis.
Materials and methods. A cohort of patients aged 25–65 years with chronic abacterial prostatitis and complaints of chronic pelvic pain was analyzed. The abacterial type of prostatitis was confirmed by bacteriological examination of expressed prostate secretions. The patients received Prostatex for 30 days according to the following scheme: 1 suppository rectally 1 time per day. The follow-up was 30 days. Before starting the drug and at the end of the 30-day course, patients completed the Chronic Prostatitis Symptom Index (NIH-CPSI) and the sexual function questionnaire. In addition, urinalysis and microscopic study of expressed prostate secretions was performed.
Results: A total of 1700 patients were included in the study. While taking the drug, there was a significant decrease in pain during digital rectal examination, as well as in the intensity of pain as a symptom of CPPS. The severity of symptoms after treatment was lower in all domains of NIH-CPSI. Microscopic study of the expressed prostate secretions during treatment showed a decrease in the number of patients with excessive number of leukocytes. The sexual function improved, while urinalysis and microscopy of expressed prostate secretions returned to the reference values.
Conclusion. The use of Prostatex for the treatment of patients with CPPS reduces the severity of pain and other symptoms of chronic prostatitis, increases sexual function and normalizes the expressed prostate secretions and urinalysis. In order to obtain data of a higher level of evidence, it is necessary to carry out randomized, blind, placebo-controlled studies.
Full Text
About the authors
A. O. Morozov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Email: morozov_a_o_1@staff.sechenov.ru
senior researcher, Institute for Urology and Reproductive Health
Russian Federation, MoscowS. V. Vovdenko
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Email: vovdenkostanislav@yandex.ru
Ph.D. student at the Institute for Urology and Reproductive Health
Russian Federation, MoscowP. Sh. Maltsagova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Email: petimat.maltsagova@mail.ru
student, Institute of the Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, MoscowL. G. Spivak
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Author for correspondence.
Email: leonid.spivak@gmail.com
Ph.D., MD, professor at the Institute for Urology and Reproductive Health
Russian Federation, MoscowReferences
- Habermacher G.M., Chason J.T., Schaeffer A.J. Prostatitis/chronic pelvic pain syndrome. Annu. Rev. Med. 2006;57:195–206.
- Chen X., Zhou Z., Qiu X., Wang B., Dai J. The Effect of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) on Erectile Function: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(1).
- Kwon J.K., Chang I.H. Pain, Catastrophizing, and Depression in Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Int. Neurourol. J. 2013;17(2):48.
- Mändar R. et al. Dramatically deteriorated quality of life in men with prostatitis‐like symptoms. Andrology. 2020;8(1):101–109.
- Rees J., Abrahams M., Doble A., Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: A consensus guideline. BJU Int. 2015;116(4):509–525.
- Zhao Q. et al. Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF-κB, MAPKs, and Nrf2 signaling pathways in rats. Andrology. 2020;8(3):747–755.
- Feng B. et al. Li-ESWT treatment reduces inflammation, oxidative stress, and pain via the PI3K/AKT/FOXO1 pathway in autoimmune prostatitis rat models. Andrology, 2021;9(5):1593–1602. doi: 10.1111/andr.13027.
- Zhang K. et al. The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. World J. Urol. 2021;39(9):3489–3495.
- Demidko Yu.L., Allenov S.N., Uzhegov T.A., Kasiteridi I.G. The effectiveness of Adenoprosin in patients with benign prostatic hyperplasia, chronic prostatitis and lower urinary tract symptoms. Effective pharmacotherapy. 2021;17(3):34–41.
- Cheng Y. et al. Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2. Inflammation 2019;42(3):1071–1081.
- Kuzmenko A.V., Vinnik Y.Y., Kuzmenko V.V., Gyaurgiev T.A. The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2021;3:70–74.
- Kuzmin I.V., Borovets S.Yu., Gorbachev A.G., Al-Shukri S.H. Prostatic bioregulatory oligopeptide prostatilen: pharmacological properties and experience of 30 years of clinical application in urology. Urological reports. 2020;10(3):243–258.
- Bely L.E. Prostate peptides in the correction of pathospermia in patients with chronic bacterial prostatitis. Medical advice. 2019;21:178–182.
- Demidko I.L., Gazimiev M.A., Baĭduvaliev A.M., Lachinov É.L., Saenko V.S. The use of vitaprost in the treatment of patients with prostate diseases. Urologiia. 2014;1:62–64.
- Savateeva-Lyubimova T.N., Sivak K.V., Malinin V.V. Influence of Prostatilen® suppositories AC for the course of experimental prostatitis. Urologiia. 2012;4:50–54.
- Karpov E.I. Modern view on the treatment of lower urinary tract syndrome: cytomedines as a class of drugs. Russian Medical Journal. 2017;25(27):1992–1996.
- Morozov A. et al. A systematic review and meta‐analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome. Prostate. 2022;82(6):633–656.
Supplementary files
